Serum Levels of Adipocyte Fatty Acid-Binding Protein Are Associated with Rapid Renal Function Decline in Patients with Type 2 Diabetes Mellitus and Preserved Renal Function

Da Hea Seo¹, Moonsuk Nam¹, Mihye Jung¹, Young Ju Suh², Seong Hee Ahn¹, Seongbin Hong¹, So Hun Kim¹

Departments of ¹Internal Medicine, ²Biomedical Sciences, Inha University School of Medicine, Incheon, Korea

Background: Recent studies have demonstrated that the levels of adipocyte fatty acid-binding protein (A-FABP) are closely associated with diabetic kidney disease (DKD) in patients with type 2 diabetes mellitus (T2DM). This study aimed to examine the association between serum A-FABP level and rapid renal function decline in patients with T2DM and preserved renal function.

Methods: This was a prospective observational study of 452 patients with T2DM and preserved renal function who had serial measurements of estimated glomerular filtration rate (eGFR). Rapid renal function decline was defined as an eGFR decline of >4% per year. The association between baseline serum A-FABP level and rapid renal function decline was investigated.

Results: Over a median follow-up of 7 years, 82 participants (18.1%) experienced rapid renal function decline. Median A-FABP levels were significantly higher in patients with rapid renal function decline, compared to non-decliners (20.2 ng/mL vs. 17.2 ng/mL, \( P=0.005 \)). A higher baseline level of A-FABP was associated with a greater risk of developing rapid renal function decline, independent of age, sex, duration of diabetes, body mass index, systolic blood pressure, history of cardiovascular disease, baseline eGFR, urine albumin creatinine ratio, total cholesterol, glycosylated hemoglobin, high-sensitivity C-reactive protein and use of thiazolidinedione, insulin, angiotensin-converting-enzyme inhibitors and angiotensin II-receptor blockers and statin (odds ratio, 3.10; 95% confidence interval, 1.53 to 6.29; \( P=0.002 \)).

Conclusion: A high level of serum A-FABP is associated with an increased risk of rapid renal function decline in patients with T2DM and preserved renal function. This suggests that A-FABP could play a role in the progression of DKD in the early stages.

Keywords: Diabetes mellitus, type 2; Diabetic nephropathies; FABP4 protein, human

INTRODUCTION

The prevalence of diabetic kidney disease (DKD) continues to increase worldwide, leading to rising morbidity and premature mortality in patients with diabetes [1]. Despite significant advances in identifying new mechanisms for DKD over the years, factors contributing to the natural course or progression of DKD in people with type 2 diabetes mellitus (T2DM) have remained unclear. DKD has been traditionally characterized by albuminuria, followed by reduced glomerular filtration rate (GFR) [2]. However, recent studies on T2DM have shown that subjects can also develop non-albuminuric renal insufficiency, suggesting that albuminuria is not a prerequisite for the development of DKD [3,4].

The Joslin Kidney Study in patients with type 1 diabetes mellitus explored the trajectories of estimated glomerular filtration rate (eGFR) decline over the years and found that most patients had a linear eGFR decline. There was a subset of patients...
who developed early rapid renal function decline, which occurred when they had normal renal function, and the decline in eGFR continued until they reached end stage renal disease (ESRD) [5]. It was suggested that rapid renal function decline is another strong predictor of progression to ESRD [5,6]. Similarly, studies in patients with T2DM also showed that most patients have a linear eGFR decline starting at an early stage and the slope varies substantially among patients [4,7,8]. Similarly, patients with T2DM also had a subgroup of patients who had steeper renal function decline [9], which predicted ESRD and premature mortality [10]; however, the definitions of rapid decline were not uniform among these studies [6,11]. Clinical factors associated with rapid renal function decline in patients with T2DM have been explored in several studies, but the findings were inconsistent [12].

Adipocyte fatty acid-binding protein (A-FABP) is an adipokine that is preferentially expressed in adipocytes [13]. Recent studies in animal models have demonstrated that circulating A-FABP is associated with glucose homeostasis via direct induction of insulin resistance [14]. Moreover, several human studies have demonstrated that serum A-FABP levels predict the development of metabolic syndrome, T2DM, carotid atherosclerosis, and nonalcoholic fatty liver disease [15-17]. Cross-sectional studies in patients with T2DM have suggested that an association exists between serum A-FABP levels and DKD. Serum A-FABP levels were reported to have a negative correlation with eGFR but a positive correlation with microalbuminuria [18-20]. Furthermore, a recent prospective study in patients with T2DM demonstrated that higher levels of A-FABP independently predicted adverse renal outcomes [21]. However, to our knowledge, the role of the level of circulating A-FABP in significant renal function decline in patients with T2DM and preserved renal function has not yet been elucidated. Therefore, we performed this prospective study to evaluate whether baseline serum A-FABP levels were independently associated with the development of rapid renal function decline in patients with T2DM and preserved renal function. Other relevant adipokines and cytokines, including pentraxin-3 (PTX3), were also examined.

**METHODS**

**Study population**

The study population consisted of 452 subjects with T2DM and preserved renal function, defined by eGFR ≥60 mL/min/1.72 m². The patients were recruited from the outpatient clinic of the Diabetes Center of Inha University Hospital in Incheon, Korea from March 2007 to December 2009. The inclusion criteria were: patients older than 20 years of age, diagnosed with T2DM based on the American Diabetes Association criteria [22], and/or being treated with oral hypoglycemic agents or insulin or lifestyle modification for known T2DM. The exclusion criteria were: patients with congestive heart failure, severe infection, uncontrolled hypertension, severe dyslipidemia (total cholesterol >400 mg/dL), a medical condition requiring active management, diabetes duration <1 year, or an eGFR <60 mL/min/1.73 m² and ≤4 annual GFR measurements during the follow-up. The study protocol was approved by the Institutional Review Board of Inha University Hospital, and all participants provided written informed consent prior to participation (IRB No. 2006-67).

**Demographic, physical, and laboratory measurements**

During interviews, trained personnel obtained medical history information from all patients. Height and weight were measured to the nearest 0.1 cm and 0.1 kg, respectively. Body mass index (BMI) was defined as weight (kg) divided by height (m) squared. Waist circumference was measured at the midpoint between the lower borders of the rib cage and the iliac crest. Blood pressure (BP) was measured after the subject had rested at least 10 minutes in a sitting position. Diabetic retinopathy was diagnosed based on funduscopic examinations. Hypertension was defined as BP ≥140/90 mm Hg or treatment with any antihypertensive drug. Cardiovascular disease (CVD) was defined as the presence of ischemic heart disease, including stable angina, acute coronary syndrome, and myocardial infarction with ST-segment elevation.

Blood samples were collected after an overnight fast of at least 10 hours and stored at −70°C until subsequent assays. Laboratory measurements, including fasting serum glucose, lipid subfractions, glycosylated hemoglobin (HbA1c), and 75 g oral glucose tolerance testing were conducted in a fasting state. The level of high-sensitivity C-reactive protein (hs-CRP) was measured using a particle-enhanced immunoturbidimetric assay (Hitachi High-Technologies Corp., Tokyo, Japan). Homeostasis model assessment of insulin resistance (HOMA-IR) levels were calculated by dividing the product of insulin (micromolits per milliliter) and glucose (millimoles per liter) concentrations by 22.5 [23]. A random urine sample was obtained for albumin creatinine ratio (ACR) measurements. Albumin-
A-FABP and early renal function decline

Baseline characteristics of study participants
The mean age of the participants was 52.6±9.2 years, 69.2% of them were men, mean duration of diabetes was 5.6±5.1 years, mean HbA1c was 7.9%±1.7%, and baseline eGFR was 85.8±14.9 mL/min/1.73 m². Of all the participants, 314 (69.5%) had normoalbuminuria, 114 (25.2%) had microalbuminuria, and 11 (2.4%) had macroalbuminuria. In total, 181 (40.0%) participants had hypertension and 17 (3.8%) had previous history of CVD. During a median follow-up of 7 years (range, 3 to 9 years), all the patients had at least four annual measurements of eGFR. Median annual eGFR decline (%) of the whole cohort was −2.0% per year. During the follow-up period, 82 patients (18.1%) developed rapid renal function decline (rapid decliners). Median annual eGFR decline (%) was −5.8% per year in rapid decliners and −0.9% per year in non-decliners (P<0.001). Three patients developed ESRD at the end of the follow-up.

Baseline characteristics of rapid decliners (n=82) and non-decliners (n=370) are summarized in Table 1. Rapid decliners were significantly older and had higher levels of baseline eGFR and total cholesterol. No difference was noted in UACR at...
## Table 1. Baseline characteristics of the study population according to the presence of rapid renal function decline

| Characteristic                        | All (n=452) | Non-decliners (n=370) | Rapid decliners (n=82) | P value |
|---------------------------------------|-------------|-----------------------|-------------------------|---------|
| Age, yr                               | 52.6±9.2    | 51.8±9.1              | 55.9±9.3                | <0.001  |
| Male sex                              | 313 (69.2)  | 255 (68.9)            | 58 (70.7)               | 0.850   |
| Diabetes duration, yr                 | 5.6±5.1     | 5.4±4.9               | 6.4±5.8                 | 0.171   |
| BMI, kg/m²                            | 25.5±3.1    | 25.5±3.2              | 25.6±2.8                | 0.809   |
| WC, cm                                | 88.3±7.5    | 88.2±7.6              | 88.3±7.1                | 0.902   |
| SBP, mm Hg                            | 124.5±14.1  | 124.1±13.6            | 126.4±16.2              | 0.253   |
| DBP, mm Hg                            | 77.5±10.0   | 77.5±9.9              | 77.6±10.6               | 0.893   |
| Hypertension                          | 181 (40.0)  | 148 (40.3)            | 33 (40.2)               | 1.000   |
| Dyslipidemia                          | 128 (28.3)  | 107 (29.5)            | 21 (25.6)               | 0.573   |
| CVD                                   | 17 (3.8)    | 16 (6.6)              | 1 (1.8)                 | 0.279   |
| Diabetic retinopathy                  | 11 (2.4)    | 10 (4.2)              | 2 (3.9)                 | 0.896   |
| HbA1c, %                              | 7.9±1.7     | 7.9±1.7               | 7.9±1.5                 | 0.828   |
| FPG, mg/dL                            | 150.0±48.6  | 151.5±49.8            | 143.7±42.3              | 0.189   |
| PP2 glucose, mg/dL                    | 279.6±99.4  | 281.9±100.2           | 269.2±95.9              | 0.434   |
| HOMA-IR, unit                         | 2.9 (1.6 to 4.4) | 2.7 (1.6 to 4.4) | 2.9 (2.0 to 4.1)        | 0.537   |
| Total cholesterol, mg/dL             | 184.6±40.2  | 182.0±38.6            | 196.4±44.9              | 0.003   |
| Triglyceride, mg/dL                   | 168.6±114.5 | 168.1±112.0           | 170.8±125.6             | 0.847   |
| HDL-C, mg/dL                          | 47.1±10.3   | 46.8±10.0             | 48.1±11.8               | 0.349   |
| LDL-C, mg/dL                          | 121.7±36.5  | 120.3±35.1            | 127.8±41.6              | 0.135   |
| hs-CRP, mg/dL                         | 0.09 (0.05 to 0.19) | 0.1 (0.1 to 0.2) | 0.1 (0.1 to 0.2)        | 0.953   |
| Albuminuria                           |             |                       |                         | 0.400   |
| Normoalbuminuria                      | 314 (69.5)  | 252 (70.6)            | 62 (75.6)               |         |
| Microalbuminuria                      | 114 (25.2)  | 97 (27.2)             | 17 (20.7)               |         |
| Macroalbuminuria                      | 11 (2.4)    | 8 (2.2)               | 3 (3.7)                 |         |
| UACR, mg/g                            | 17.0 (9.7 to 37) | 18.0 (10.0 to 38.0) | 15.2 (8.9 to 29.0)      | 0.164   |
| eGFR, mL/min/1.73 m²                  | 85.8±14.9   | 84.8±14.9             | 90.2±14.2               | 0.003   |
| eGFR slope, %/yr                      | −2.0 (−3.5 to −0.6) | −0.9±1.9             | −5.8±2.9                | <0.001  |
| Diabetes medications                  |             |                       |                         |         |
| Metformin                             | 330 (73.0)  | 238 (71.9)            | 92 (78.0)               | 0.246   |
| Sulfonylurea                          | 207 (45.8)  | 267 (72.8)            | 63 (76.8)               | 0.537   |
| TZD                                   | 56 (12.4)   | 169 (46.0)            | 38 (46.3)               | 1.000   |
| Insulin                               | 62 (13.7)   | 50 (13.6)             | 6 (7.3)                 | 0.168   |
| Use of statin                         | 148 (32.7)  | 96 (31.0)             | 52 (37.7)               | 0.198   |
| Use of ACEi/ARB                       | 176 (38.9)  | 50 (13.6)             | 12 (14.6)               | 0.950   |
| A-FABP, µg/L                          | 17.72 (11.88 to 25.51) | 17.2 (11.2 to 24.1) | 20.2 (14.1 to 29.9)     | 0.005   |
| Men                                   | 15.81 (10.82 to 21.40) | 15.2 (10.5 to 21.1) | 17.5 (12.2 to 24.4)     | 0.037   |
| Women                                 | 23.11 (15.72 to 33.09) | 22.1 (15.3 to 30.8) | 31.5 (20.7 to 50.7)     | 0.007   |
| Total adiponectin, µg/mL              | 3.9 (2.8 to 6.0) | 3.9 (2.8 to 6.1) | 3.9 (2.8 to 6.3)        | 0.876   |
| HMW adiponectin, µg/mL                | 1.2 (0.6 to 2.4) | 1.3 (0.6 to 2.4) | 1.3 (0.6 to 2.6)        | 0.809   |
| Interleukin-6, pg/mL                  | 0.9 (0.5 to 1.5) | 0.9 (0.5 to 1.5) | 0.9 (0.7 to 1.3)        | 0.179   |

(Continued to the next page)
baseline between the groups. The majority of the rapid decliners had normoalbuminuria at baseline (75.6%), which was comparable with that of the non-decliners (70.6%).

### Levels of serum A-FABP and other cytokines according to the presence of rapid renal function decline

Baseline median serum A-FABP levels were significantly higher in rapid decliners compared to non-decliners (20.2 µg/L vs. 17.2 µg/L, *P* = 0.005) (Table 1, Fig. 1B). When stratified for sex, similar findings were noted for both men and women (Table 1). Serum A-FABP levels were significantly higher in women than in men (23.1 µg/L vs. 15.8 µg/L, *P* < 0.001) (Fig. 1A). Consistent with previous reports [12,13], patients with micro or macroalbuminuria had significantly higher median serum A-FABP concentrations than those with normoalbuminuria (19.5 µg/L vs. 16.6 µg/L, *P* = 0.042) (Fig. 1C). Median serum levels of total adiponectin, HMW, IL-6, TNF-α, and PTX3 showed no difference between rapid decliners and non-decliners.

### Table 1. Continued

| Characteristic     | All (n=452) | Non-decliners (n=370) | Rapid decliners (n=82) | *P* value |
|--------------------|-------------|-----------------------|------------------------|-----------|
| TNF-α, pg/mL       | 1.2 (0.8 to 2.0) | 1.3 (0.8 to 2.0) | 1.2 (0.8 to 2.1) | 0.480     |
| PTX3, ng/mL        | 1.3 (0.8 to 2.1) | 1.2 (0.8 to 2.2) | 1.4 (0.9 to 2.1) | 0.237     |

Values are presented as mean ± standard deviation, number (%), or median (interquartile range). *P* values refer to the unpaired *t* test or the chi-square test (for categorical variables) between non-decliners and rapid decliners.

BMI, body mass index; WC, waist circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure; CVD, cardiovascular disease; HbA1c, glycosylated hemoglobin; FPG, fasting plasma glucose; PP2, 2-hour postprandial; HOMA-IR, homeostatic model assessment of insulin resistance; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; hs-CRP, high-sensitivity C-reactive protein; UACR, urine albumin creatinine ratio; eGFR, estimated glomerular filtration rate; TZD, thiazolidinedione; ACEi, angiotensin-converting-enzyme inhibitor; ARB, angiotensin II-receptor blocker; A-FABP, adipocyte fatty acid-binding protein; HMW, high molecular weight adiponectin; TNF-α, tumor necrosis factor-α; PTX3, pentraxin-3.

*P* < 0.001 for A-FABP for men vs. women.

### Fig. 1. Comparison of plasma adipocyte fatty acid–binding protein (A-FABP) levels (µg/L) based on sex (A), the presence of rapid renal function decline (B), or albuminuria (C). The bottom of the box plots indicates the 25th percentile and the top indicates the 75th percentile. The middle line of the box indicates the median. The lower and the upper ends of the whiskers indicate the minimum and the maximum observations below the upper fence (1.5 interquartile range above the 75th percentile), respectively.

### Table 2. Association between annual renal function decline (%) and cytokines

| Variable               | Unadjusted | Adjusted* |
|------------------------|------------|-----------|
|                        | *r*        | *P* value | *r*        | *P* value |
| A-FABP, µg/L           | -0.055     | 0.24      | -0.150     | 0.005     |
| hs-CRP, mg/dL          | -0.013     | 0.78      | 0.001      | 0.99      |
| Fibrinogen, mg/dL      | -0.064     | 0.23      | -0.046     | 0.39      |
| Total adiponectin, µg/mL| -0.023     | 0.63      | 0.071      | 0.19      |
| HMW adiponectin, µg/mL | -0.039     | 0.40      | 0.055      | 0.31      |
| Interleukin-6, pg/mL   | -0.043     | 0.36      | 0.051      | 0.35      |
| TNF-α, pg/mL           | 0.037      | 0.43      | -0.045     | 0.40      |
| PTX3, ng/mL            | -0.042     | 0.37      | -0.070     | 0.19      |

A-FABP, adipocyte fatty acid-binding protein; hs-CRP, high-sensitivity C-reactive protein; HMW, high molecular weight adiponectin; TNF-α, tumor necrosis factor-α; PTX3, pentraxin-3.

*Partial Spearman’s correlation coefficients (*r*) are presented after adjustment for age, sex, body mass index, glycosylated hemoglobin, and baseline estimated glomerular filtration rate.

https://e-dmj.org  Diabetes Metab J 2020;44:875-886  879
### Table 3. Characteristics according to A-FABP tertile levels

| Characteristic                  | Tertiles of A-FABP levels, µg/L | P for trend |
|--------------------------------|----------------------------------|------------|
|                                | 1 (<12.25 [men], <18.68 [women]) |            |
|                                | 2 (12.25–19.44 [men], 18.68–30.13 [women]) |            |
|                                | 3 (>19.44 [men], >30.13 [women]) |            |
| Age, yr                        | 51.2±8.0                         | 52.4±8.9   | 54.1±10.5 | 0.005 |
| Diabetes duration, yr          | 4.8±4.6                          | 5.2±4.7    | 6.8±5.6  | <0.001 |
| BMI, kg/m^2                    | 25.7±3.2                         | 25.3±2.8   | 25.5±3.4 | 0.50  |
| WC, cm                         | 88.5±7.8                         | 87.6±6.8   | 88.6±7.8 | 0.97  |
| WHR                            | 0.9±0.0                          | 0.9±0.0    | 0.9±0.1  | 0.65  |
| SBP, mm Hg                     | 125.4±14.2                       | 124.8±14.1 | 123.5±14.2 | 0.23 |
| DBP, mm Hg                     | 78.5±9.7                         | 77.3±10.3  | 76.7±9.9 | 0.12  |
| Hypertension                   | 60 (40.3)                        | 52 (34.7)  | 69 (46.0) | 0.14  |
| Dyslipidemia                   | 43 (29.3)                        | 41 (27.5)  | 44 (29.5) | 0.92  |
| CVD                            | 5 (5.1)                          | 4 (3.9)    | 8 (8.2)  | 0.39  |
| Diabetic retinopathy           | 32 (25.2)                        | 30 (24.2)  | 34 (27.1) | 0.58  |
| HbA1c, %                       | 7.8±1.5                          | 8.1±1.7    | 7.9±1.7  | 0.50  |
| FPG, mg/dL                     | 148.8±46.6                       | 151.9±51.1 | 149.4±48.1 | 0.92 |
| PP2 glucose, mg/dL             | 284.0±99.7                       | 272.4±97.7 | 282.4±101.4 | 0.93 |
| HOMA-IR, unit                  | 2.4 (1.5 to 4.0)                 | 3.0 (1.9 to 4.7) | 2.6 (1.8 to 4.5) | 0.79 |
| Total cholesterol, mg/dL       | 181.5±42.3                       | 190.1±41.2 | 182.3±36.3 | 0.88 |
| Triglyceride, mg/dL            | 169.9±120.7                      | 161.4±95.4 | 174.7±125.6 | 0.72 |
| HDL-C, mg/dL                   | 47.8±10.7                        | 46.6±10.4  | 46.8±9.9  | 0.39  |
| LDL-C, mg/dL                   | 118.6±38.9                       | 126.3±34.3 | 120.1±35.8 | 0.71  |
| hs-CRP, mg/dL                  | 0.08 (0.04 to 0.18)              | 0.10 (0.05 to 0.19) | 0.10 (0.06 to 0.22) | 0.08 |
| eGFR, mL/min/1.73 m^2          | 87.1±15.3                        | 86.6±14.7  | 83.6±14.6 | 0.04  |
| eGFR slope, %/yr               | −1.5 (−2.8 to 0.0)               | −2.0 (−3.3 to −0.5) | −2.1 (−4.0 to −0.4) | 0.03 |
| UACR, mg/g                     | 20.0 (9.1 to 32.5)               | 14.0 (8.2 to 30.0) | 19.4 (11.6 to 38.6) | 0.46 |
| Albuminuria                    |                                   |            | 0.35    |
| Normalalbuminuria              | 107 (74.3)                       | 109 (74.1) | 98 (66.2) |            |
| Microalbuminuria               | 34 (23.6)                        | 36 (24.5)  | 44 (29.7) |            |
| Macroalbuminuria               | 3 (2.1)                          | 2 (1.4)    | 6 (4.1)  |            |
| Rapid renal function decliners | 19 (12.7)                        | 25 (16.6)  | 38 (25.2) | 0.016 |

**Diabetes medications**

| Metformin                      | 107 (71.8)                       | 107 (71.3) | 116 (77.3) | 0.43 |
| Sulfonylurea                   | 65 (43.6)                        | 73 (48.7)  | 69 (46.0)  | 0.68 |
| TZD                            | 22 (14.8)                        | 19 (12.7)  | 15 (10.0)  | 0.46 |
| Insulin                        | 17 (11.4)                        | 20 (13.3)  | 25 (16.7)  | 0.41 |

**Use of ACEi/ARB**

| Use of ACEi/ARB                | 64 (43.0)                        | 47 (31.3)  | 65 (43.3)  | 0.05 |

**A-FABP, µg/L**

| A-FABP, µg/L                    | 9.84 (8.42 to 11.85)             | 17.32 (14.36 to 20.45) | 30.36 (22.07 to 38.90) | < 0.001 |

**Total adiponectin, µg/mL**

| Total adiponectin, µg/mL        | 3.89 (2.84 to 6.17)              | 3.68 (2.72 to 5.55) | 3.94 (2.99 to 6.12) | 0.45 |

**HMW adiponectin, µg/mL**

| HMW adiponectin, µg/mL          | 1.29 (0.59 to 2.59)              | 1.22 (0.60 to 2.39) | 1.35 (0.67 to 2.66) | 0.87 |

**Interleukin-6, pg/mL**

| Interleukin-6, pg/mL            | 0.87 (0.54 to 1.53)              | 0.93 (0.57 to 1.47) | 0.87 (0.59 to 1.42) | 1.00 |

(Continued to the next page)
Correlation between annual renal decline (%) and serum level of A-FABP and other adipocytokines

As shown in Table 2, partial Spearman’s correlation analyses were performed to investigate the correlations between annual renal function decline (%) and serum levels of adipokines or cytokines after adjusting for clinical risk factors, including age, sex, BMI, HbA1c, and baseline eGFR. Serum A-FABP showed a negative correlation with annual renal function decline (%) (r = –0.150, P = 0.005). No significant correlation was observed between annual renal function decline (%) and other adipokines or cytokines.

Independent association between serum A-FABP level and rapid renal function decline

To assess the characteristics of the patients according to the A-FABP levels, the participants were subgrouped into tertiles based on serum A-FABP levels. The incidence of rapid renal function decline in the lowest (T1) to highest (T3) A-FABP tertiles was 12.7%, 16.6%, and 25.2%, respectively (Prenal 0.016) (Table 3). Participants in the higher tertiles were older, had a longer duration of diabetes, lower baseline eGFR, and faster eGFR decline per year (%), but no differences were found in baseline UACR. However, the A-FABP level was not significantly associated with other inflammatory markers. Multivariable logistic regression analysis showed that baseline serum A-FABP level was independently associated with a greater risk of rapid renal function decline (Model 1; odds ratio [OR], 1.81; 95% CI, 1.17 to 2.80) after adjustment for age (Table 4). This association remained significant after further adjustment for other factors, including sex, duration of diabetes, BMI, SBP, history of cardiovascular disease, baseline eGFR, UACR, total cholesterol, glycosylated hemoglobin, hs-CRP and use of thiazolidinedione, insulin, angiotensin-converting-enzyme inhibitor/angiotensin II-receptor blocker and statin. OR, odds ratio; A-FABP, adipocyte fatty acid-binding protein; CI, confidence interval. *Values are presented adjusted OR of log-transformed A-FABP.

### Table 3. Continued

| Characteristic | Tertiles of A-FABP levels, µg/L | P for trend |
|---------------|---------------------------------|------------|
|               | 1 (<12.25 [men], 18.68 [women]) |            |
|               | 2 (12.25–19.44 [men], 18.68–30.13 [women]) |            |
|               | 3 (>19.44 [men], >30.13[women]) |            |
| TNF-α, pg/mL  | 1.31 (0.87 to 2.07) | 1.28 (0.83 to 1.94) | 1.21 (0.76 to 2.16) | 0.57 |
| PTX3, ng/mL   | 1.31 (0.62 to 2.24) | 1.22 (0.79 to 2.20) | 1.37 (0.91 to 2.13) | 0.25 |

Values are presented as mean±standard deviation, number (%), median (interquartile range). A-FABP, adipocyte fatty acid-binding protein; BMI, body mass index; WC, waist circumference; WHR, waist hip ratio; SBP, systolic blood pressure; DBP, diastolic blood pressure; CVD, cardiovascular disease; HbA1c, glycosylated hemoglobin; FPG, fasting plasma glucose; PP2, 2-hour post prandial; HOMA-IR, homeostatic model assessment of insulin resistance; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; hs-CRP, high-sensitivity C-reactive protein; eGFR, estimated glomerular filtration rate; UACR, urine albumin creatinine ratio; TZD, thiazolidinedione; ACEi, angiotensin-converting-enzyme inhibitor; ARB, angiotensin II-receptor blocker; HMW, high molecular weight adiponectin; TNF-α, tumor necrosis factor-α; PTX3, pentraxin-3.

### Table 4. OR for rapid renal function decline conferred to the A-FABP levels

| Variable | All | Male | Female |
|----------|-----|------|--------|
|          | OR* (95% CI) | P value | OR* (95% CI) | P value | OR* (95% CI) | P value |
| Model 1  | 1.81 (1.17–2.80) | 0.002 | 1.68 (0.97–2.91) | 0.063 | 3.27 (1.31–8.15) | 0.011 |
| Model 2  | 3.04 (1.53–6.06) | 0.002 | 2.51 (1.08–5.86) | 0.033 | 5.63 (1.33–23.88) | 0.019 |
| Model 3  | 3.10 (1.53–6.29) | 0.002 | 2.65 (1.10–6.38) | 0.030 | 5.65 (1.17–27.19) | 0.031 |

All models were constructed by the logistic regression analysis. Model 1: adjusted for age. Model 2: model 1+adjustments for sex, duration of diabetes, body mass index, systolic blood pressure, history of cardiovascular disease, baseline estimated glomerular filtration rate, log urine albumin creatinine ratio, total cholesterol, glycosylated hemoglobin, and log high-sensitivity C-reactive protein. Model 3: model 2+adjustment for use of thiazolidinedione, insulin, angiotensin-converting-enzyme inhibitor/angiotensin II-receptor blocker and statin. OR, odds ratio; A-FABP, adipocyte fatty acid-binding protein; CI, confidence interval. *Values are presented adjusted OR of log-transformed A-FABP.
DISCUSSION

In this prospective study of patients with T2DM and preserved renal function, we demonstrated that the baseline serum A-FABP level was independently associated with the development of early rapid renal function decline during 7 years of follow-up. Higher baseline serum A-FABP level was associated with a greater risk of developing rapid renal function decline in patients with T2DM and preserved renal function, independent of other clinical risk factors.

A few studies have demonstrated that there is an independent association between A-FABP and diabetic nephropathy [18-20]. However, most of these published studies are limited by small sample sizes and cross-sectional settings. A prospective study by the Hong Kong West Diabetes Registry was published while our manuscript was in preparation and showed that the level of circulating A-FABP was independently associated with the development of adverse renal outcomes in patients with T2DM, suggesting a significant role of serum A-FABP in DKD as seen in our study [21]. In the present study, we found that a higher baseline serum A-FABP level was independently associated with the development of early rapid renal function decline in individuals with T2DM and preserved renal function. As filtration through the kidneys is an important route of A-FABP clearance [27], we exclusively enrolled individuals with preserved renal function whereas other studies had also included participants with impaired renal function. Consistent with the results of previous studies on rapid renal function decline in patients with T2DM [7,11], the overall incidence of rapid renal function decline in the current study was 18.1% during the median follow-up of 7 years. Patients in the highest and lowest A-FABP tertiles had incidence rates of 25.2% and 16.6%, respectively.

Serum A-FABP levels were significantly higher in females than in males as previously reported [16,28]. Although the reason for this difference is not clearly understood it has been speculated that sex hormones, especially androgen, play critical roles in the production and distribution of body fat [29], which regulates circulating A-FABP levels [30]. When analysis was done separately for males and females, serum levels of circulating A-FABP remained independently associated with rapid renal function decline in both males and females.

Although the exact mechanisms underlying rapid renal function decline are unknown, our findings may implicate the potential role of A-FABP in the development and progression of DKD, especially in the early stages. While the Hong Kong study examined the association between baseline serum A-FABP level and hard renal outcomes such as a sustained 40% decline in eGFR, ESRD requiring renal replacement therapy or kidney transplantation, or death from renal causes [21], the primary endpoint in the present study was early rapid renal function decline, an outcome that can more sensitively identify patients that are at high risk during the early stages. Early rapid renal function decline is considered a unidirectional process that occurs while patients have normal kidney function and steadily progresses to ESRD [5]; yet, there is no effective prognostic tool or marker that identifies rapid decliners in clinical settings. While both albuminuria and reduced eGFR are independent risk factors of ESRD [31], they are of little value to distinguish non-decliners from rapid decliners during the early stages. Conversely, this study demonstrated the potential implication of serum A-FABP as a clinical marker for identifying rapid decliners among patients with T2DM and normal kidney function. It is particularly relevant, as, at present, a good prognostic test to identify rapid decliners while they have normal renal function is not available. Furthermore, there is emerging evidence suggesting an increase in the prevalence of DKD without accompanying albuminuria [3], and our study demonstrated that baseline serum A-FABP was significantly associated with rapid renal function decline even after adjustment for baseline UACR. Collectively, these findings provide further evidence for the potential role of A-FABP in the pathogenesis of DKD during the earlier stages when no clinical manifestation is present.

Although the exact role of A-FABP in the pathogenesis of rapid renal function decline is not fully understood and is beyond the scope of the current study, there may be a few possible mechanisms. Previous animal studies on A-FABP−/− mice showed that they were protected from the development of obesity-induced insulin resistance and diet-induced atherosclerosis [32], and mice treated with an A-FABP inhibitor demonstrated improvement in metabolic profiles as well as marked reduction in atherosclerotic lesions [33]. Similar findings were also noted in humans; where, increased A-FABP synthesis in atherosclerotic plaques was associated with disease severity [32]. As atherosclerosis plays a critical role in the development of early DKD [34], A-FABP may promote atherosclerotic disease, which, in turn, can lead to rapid renal function decline in patients with T2DM. These findings are further supported by our recent study in patients with T2DM and pre-
erved renal function; where, there was a strong association between carotid atherosclerosis and rapid renal function decline [35].

Secondly, increased levels of A-FABP may be an indicator of the abnormal angiogenesis that is involved in the pathogenesis of the early stages of DKD. A-FABP has been primarily regarded as an adipocyte and macrophage-specific intracellular lipoprotein binding protein [36]. However, recent studies have demonstrated that A-FABP is also expressed in microvascular endothelial cells, including peritubular capillaries of the kidney, in an angiogenesis-dependent manner in both mice and humans [36]. Previous studies on DKD indicated that abnormal angiogenesis is involved in the development of diabetic nephropathy, which is triggered by high glucose levels as well as glomerular hypertension [37]. Additionally, upregulation of vascular endothelial growth factor expression was also observed, which acts as a mediator of abnormal angiogenesis in diabetic nephropathy as well as a regulator of A-FABP in endothelial cells [36, 37]. Thus, an elevated serum A-FABP level at baseline may indicate the increased expression of A-FABP in the renal tubules as well as endothelial cells of tubular capillaries, suggesting that abnormal angiogenesis and accumulation of macrophages and proinflammatory cytokines occur in the kidneys prior to the impairment of renal function. Accordingly, measuring serum A-FABP levels may offer additive information to identify the patients at risk of developing early DKD.

Increasing evidence also points to the critical roles of proinflammatory cytokines in the development and progression of DKD. Longitudinal studies have shown a positive relationship between hs-CRP, TNF-α, IL-6, and progression of DKD, which is often correlated with albuminuria [38, 39]. Another study also demonstrated that both serum and urinary TNF-α levels were increased in diabetic patients with albuminuria, but no correlation was found in patients with normoalbuminuria [40]. Urine concentrations of cytokines, such as IL-6, were reported to be markedly elevated in rapid renal function decliners with albuminuria [5]. However, in the present study, no significant association was observed between baseline levels of inflammatory cytokines and rapid renal function decline; this may be due to differences in the study population, study endpoints, and ethnicity. In fact, the majority of the subjects in our study had normoalbuminuria at baseline (69.5%) and the proportion of subjects with normoalbuminuria was similar between rapid decliners and non-decliners. Regarding PTX3, a vascular inflammatory marker, inconsistent results have been observed in patients with DKD [41]. In our study, no association was found between PTX3 levels and rapid renal function decline.

The strength of this study includes the prospective design with serial measurements of kidney function to accurately estimate the annual eGFR decline and examine the association between rapid renal function decline and adipokines. We also confined the subjects to those with preserved renal function to assess the association between baseline serum A-FABP levels and early progressive renal disease. Moreover, our cohort consists of a large number of participants from a homogeneous population and the follow-up period was 7 years. We also measured other proinflammatory cytokines and adipokines along with serum A-FABP. To our knowledge, this is the first prospective study showing that high A-FABP serum levels at baseline are associated with increased risk of rapid renal function decline in Asian patients with T2DM and preserved renal function.

The present study, however, has some limitations. First, because our cohort comprised Korean patients with T2DM who followed at a single, tertiary-level hospital, our results may not be directly applicable to the general population. Second, there was no direct measurement of GFR but we employed CKD-EPI equations, which have been widely used by many studies. In addition, we measured serial values over time to identify the rate of decline in eGFR that was approximated using linear slopes; the use of such slopes likely smoothed out the variability in individual GFR estimates and measurements. Third, the serum A-FABP level was determined from a single-point blood sample at baseline. Serial sampling during the natural course of T2DM could help in further elucidating the role of A-FABP in the pathophysiological mechanisms of the development and progression of DKD. Lastly, renal biopsy was not performed in the majority of subjects in our study; hence, the histological diagnosis of DKD could not be confirmed.

In conclusion, higher levels of serum A-FABP are associated with increased risk of rapid renal function decline in patients with T2DM and preserved renal function. Along with its role as a metabolic risk marker, increased levels of serum A-FABP in diabetic patients may serve as a clinical marker for early progressive renal disease, which will allow early implementation of an intensive treatment in diabetic patients with normal renal function. Further studies are warranted to elucidate the role of A-FABP in the pathophysiological mechanisms involved in the development and progression of DKD.
CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

AUTHOR CONTRIBUTIONS

Conception or design: D.H.S., S.H.K.
Acquisition, analysis, or interpretation of data: D.H.S., M.N., M.J., Y.J.S., S.H.A., S.H., S.H.K.
Drafting the work or revising: D.H.S., M.N., M.J., S.H.A., S.H., S.H.K.
Final approval of the manuscript: S.H.K.

ORCID

Da Hea Seo https://orcid.org/0000-0003-2767-0293
So Hun Kim https://orcid.org/0000-0002-2554-3664

ACKNOWLEDGMENTS

This work was supported by an Inha University Hospital Research Grant. No funding sources were involved in the study.

REFERENCES

1. Tuttle KR, Bakris GL, Bilous RW, Chiang JL, de Boer IH, Goldstein-Fuchs J, Hirsch IB, Kalantar-Zadeh K, Narva AS, Navaneethan SD, Neumiller JJ, Patel UD, Ratner RE, Whaley-Connell AT, Molitch ME. Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes Care 2014;37:2864-83.
2. de Boer IH, Steffes MW. Glomerular filtration rate and albuminuria: twin manifestations of nephropathy in diabetes. J Am Soc Nephrol 2007;18:1036-7.
3. Retnakaran R, Cull CA, Thorne KJ, Adler AI, Holman RR; UKPDS Study Group. Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes 2006;55:1832-9.
4. Vistisen D, Andersen GS, Hulman A, Persson F, Rossing P, Jorgensen ME. Progressive decline in estimated glomerular filtration rate in patients with diabetes after moderate loss in kidney function—even without albuminuria. Diabetes Care 2019;42:1886-94.
5. Krolevskski AS. Progressive renal decline: the new paradigm of diabetic nephropathy in type 1 diabetes. Diabetes Care 2015;38:954-62.
6. Pavkov ME, Knowler WC, Lemley KV, Mason CC, Myers BD, Nelson RG. Early renal function decline in type 2 diabetes. Clin J Am Soc Nephrol 2012;7:78-84.
7. Kroleveski AS, Skupien J, Rossing P, Warram JH. Fast renal decline to end-stage renal disease: an unrecognized feature of nephropathy in diabetes. Kidney Int 2017;91:1300-11.
8. Jiang G, Luk AOU, Tam CHT, Xie F, Carstensen B, Lau ESH, Lim CKP, Lee HM, Ng ACW, Ng MCY, Ozaki R, Kong APS, Chow CC, Yang X, Lan HY, Tsui SKW, Fan X, Szeto CC, So WY, Chan JCN, Ma RCW; Hong Kong Diabetes Register TRS Study Group. Progression of diabetic kidney disease and trajectory of kidney function decline in Chinese patients with type 2 diabetes. Kidney Int 2019;95:178-87.
9. Warren B, Rebolholz CM, Sang Y, Lee AK, Coresh J, Selvin E, Grams ME. Diabetes and trajectories of estimated glomerular filtration rate: a prospective cohort analysis of the atherosclerosis risk in communities study. Diabetes Care 2018;41:1646-53.
10. Coresh J, Turin TC, Matsushita K, Sang Y, Ballew SH, Appel LJ, Arima H, Chadban SJ, Cirillo M, Djurdjev O, Green JA, Heine GH, Inker LA, Irie F, Ishani A, Ix JH, Kovesdy CP, Marks A, Okhobo T, Shaley V, Shankar A, Wen CP, de Jong PE, Iseki K, Stengel B, Gansevoort RT, Levey AS. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA 2014;311:2518-31.
11. Zoppini G, Targher G, Ortaldo V, Negri C, Stoico V, Bonora E. Predictors of estimated GFR decline in patients with type 2 diabetes and preserved kidney function. Clin J Am Soc Nephrol 2012;7:401-8.
12. Sheen YJ, Sheu WH. Risks of rapid decline renal function in patients with type 2 diabetes. World J Diabetes 2014;5:835-46.
13. Kralisch S, Fasshauer M. Adipocyte fatty acid binding protein: a novel adipokine involved in the pathogenesis of metabolic and vascular disease? Diabetologia 2013;56:10-21.
14. Cao H, Sekiya M, Ertunc ME, Burak MF, Mayers JR, White A, Inouye K, Rickey LM, Ercai BC, Furuhashi M, Tuncman G, Hotamisligil GS. Adipocyte lipid chaperone AP2 is a secreted adipokine regulating hepatic glucose production. Cell Metab 2013;17:768-78.
15. Tso AW, Xu A, Sham PC, Wat NM, Wang Y, Fong CH, Cheung BM, Janus ED, Lam KS. Serum adipocyte fatty acid binding protein as a new biomarker predicting the development of type 2 diabetes: a 10-year prospective study in a Chinese cohort. Diabet Med 2007;30:2667-72.
16. Koh JH, Shin YG, Nam SM, Lee MY, Chung CH, Shin JY. Se-
rum adipocyte fatty acid-binding protein levels are associated with nonalcoholic fatty liver disease in type 2 diabetic patients. Diabetes Care 2009;32:147-52.

17. Yeung DC, Xu A, Cheung CW, Wat NM, Yau MH, Fong CH, Chau MT, Lam KS. Serum adipocyte fatty acid-binding protein levels were independently associated with carotid atherosclerosis. Arterioscler Thromb Vasc Biol 2007;27:1796-802.

18. Cabre A, Lazaro I, Girona J, Manzanares JM, Marimon F, Plana N, Heras M, Masana L. Plasma fatty acid-binding protein 4 increases with renal dysfunction in type 2 diabetic patients without microalbuminuria. Clin Chem 2008;54:181-7.

19. Yeung DC, Xu A, Tso AW, Chow WS, Wat NM, Fong CH, Tam S, Sham PC, Lam KS. Circulating levels of adipocyte and epidermal fatty acid-binding proteins in relation to nephropathy staging and macrovascular complications in type 2 diabetic patients. Diabetes Care 2009;32:132-4.

20. Torunier F, Altinova AE, Akturk M, Yau MH, Arslan E, Bukan N, Kan E, Yetkin I, Arslan M. The relationship between adipocyte fatty acid binding protein-4, retinol binding protein-4 levels and early diabetic nephropathy in patients with type 2 diabetes. Diabetes Res Clin Pract 2011;91:203-7.

21. Lee CH, Cheung CYY, Lui DTY, Yuen MMA, Fong CHY, Chow WS, Xu A, Lam KSL. Prospective associations of circulating adipocyte fatty acid-binding protein levels with risks of renal outcomes and mortality in type 2 diabetes. Diabetologia 2019;62:169-77.

22. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2004;27 Suppl 1:S5-10.

23. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9.

24. Inker LA, Astor BC, Fox CH, Isaakova T, Lash JP, Peralta CA, Kurella Tamura M, Feldman HI. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis 2014;63:713-35.

25. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604-12.

26. Rifkin DE, Shlipak MG, Katz R, Fried LF, Siscovick D, Chonchol M, Newman AB, Sarnak MJ. Rapid kidney function decline and mortality risk in older adults. Arch Intern Med 2008;168:2212-8.

27. Sommer G, Ziegelmeier M, Bachmann A, Kralisch S, Lossner U, Kratzsch J, Bluher M, Stumvoll M, Fasshauer M. Serum levels of adipocyte fatty acid-binding protein (AFABP) are increased in chronic haemodialysis (CD). Clin Endocrinol (Oxf) 2008;69:901-5.

28. Li JC, Wu DA, Hou JS, Subeq YM, Chen HD, Hsu BG. High serum adipocyte fatty acid binding protein is associated with metabolic syndrome in patients with type 2 diabetes. J Diabetes Res 2016;2016:8380279.

29. Mongraw-Chaffin ML, Anderson CA, Allison MA, Ouyang P, Szklo M, Vaidya D, Woodward M, Golden SH. Association between sex hormones and adiposity: qualitative differences in women and men in the multi-ethnic study of atherosclerosis. J Clin Endocrinol Metab 2015;100:E596-600.

30. Xu A, Wang Y, Xu JY, Stejskal D, Tam S, Zhang J, Wat NM, Wong WK, Lam KS. Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin Chim Acta 2006;352:405-13.

31. Ninomiya T, Perkovic V, de Galan BE, Zoungas S, Pillai A, Jardine M, Patel A, Cass A, Neal B, Poulter N, Mogensen CE, Cooper M, Marre M, Williams B, Hamet P, Mancia G, Woodward M, Macmahon S, Chalmers J; ADVANCE Collaborative Group. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 2009;20:1813-21.

32. Makowski L, Boord JB, Maeda K, Babaev VR, Uysal KT, Morgan MA, Parker RA, Suttles J, Fazio S, Hotamisligil GS, Linton MF. Lack of macrophage fatty-acid-binding protein ap2 protects mice deficient in apolipoprotein E against atherosclerosis. Nat Med 2001;7:699-705.

33. Furuhashi M, Tuncman G, Gorgun CZ, Makowski L, Atsumi G, Vaillancourt E, Kono K, Babaev VR, Fazio S, Linton MF. Lack of macrophage fatty-acid-binding protein ap2 protects mice deficient in apolipoprotein E against atherosclerosis. Nat Med 2001;7:699-705.

34. Makowski L, Boord JB, Maeda K, Babaev VR, Uysal KT, Morgan MA, Parker RA, Suttles J, Fazio S, Hotamisligil GS, Linton MF. Lack of macrophage fatty-acid-binding protein ap2 protects mice deficient in apolipoprotein E against atherosclerosis. Nat Med 2001;7:699-705.

35. Nohtomi T, Kondo N, Kono K, Babaev VR, Fazio S, Linton MF. Lack of macrophage fatty-acid-binding protein ap2 protects mice deficient in apolipoprotein E against atherosclerosis. Nat Med 2001;7:699-705.
36. Elmasri H, Karaaslan C, Teper Y, Ghelfi E, Weng M, Ince TA, Kozakewich H, Bischoff J, Cataltepe S. Fatty acid binding protein 4 is a target of VEGF and a regulator of cell proliferation in endothelial cells. FASEB J 2009;23:3865-73.
37. Nakagawa T, Sato W, Kosugi T, Johnson RJ. Uncoupling of VEGF with endothelial NO as a potential mechanism for abnormal angiogenesis in the diabetic nephropathy. J Diabetes Res 2013;2013:184539.
38. Navarro JF, Mora C, Maca M, Garca J. Inflammatory parameters are independently associated with urinary albumin in type 2 diabetes mellitus. Am J Kidney Dis 2003;42:53-61.
39. Stehouwer CD, Gall MA, Twisk JW, Knudsen E, Emeis JJ, Parving HH. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. Diabetes 2002;51:1157-65.
40. Navarro JF, Mora C, Muros M, Garcia J. Urinary tumour necrosis factor-alpha excretion independently correlates with clinical markers of glomerular and tubulointerstitial injury in type 2 diabetic patients. Nephrol Dial Transplant 2006;21:3428-34.
41. Uzun S, Ozari M, Gursu M, Karadag S, Behlul A, Sari S, Koldas M, Demir S, Karaali Z, Ozturk S. Changes in the inflammatory markers with advancing stages of diabetic nephropathy and the role of pentraxin-3. Ren Fail 2016;38:1193-8.